New Protocol: Acalabrutinib with R-Bendamustine for Mantle Cell Lymphoma
Study
Randomized, double-blind, placebo-controlled, multicenter trial (ECHO)
|
Previously untreated Mantle Cell Lymphoma (MCL) who were ineligible for transplant (N=598)
|
Acalabrutinib + R-Bendamustine x 6 => rituximab-acalabrutinib maintenance vs. R-Bendamustine + placebo x 6 => rituximab + placebo maintenance
|
Efficacy
ORR; 91% vs. 88% (BR + acalabrutinib vs. BR + placebo)
|
CR: 67% vs. 54%
|
mPFS 66.4 mos vs. 49.6 mos (HR: 0.73 [0.57 – 0.94])
|
Safety
Grade >=3 AEs: Neuropenia (56% vs. 51%), Rash (12% vs. 3%),
|
FDA FDA Package Insert for Acalabrutinib
Reviewed by Ulas D. Bayraktar, MD on Jan 19, 2025